Monoclonal Antibodies
Aplitibart for Metastatic Colorectal Cancer
Recruiting1 awardPhase 1
Denver, Colorado
This trial is testing a new drug called aplitibart with standard chemotherapy and another drug in patients with metastatic colorectal cancer that has come back or spread. The treatment works by killing cancer cells and cutting off their nutrient supply.
Alkylating agents
Seclidemstat + Chemotherapy for Ewing Sarcoma
Recruiting1 awardPhase 1
Los Angeles, California
This trial tests seclidemstat alone and with other drugs in patients with specific types of sarcoma, especially those who haven't responded to other treatments. The treatment aims to block cancer growth and use chemotherapy to kill cancer cells.
Proton Beam Therapy
Intensity Modulated Proton Radiation for Brain & Spine Cancer
Recruiting1 award
Boston, Massachusetts
This trial is testing a new way to give proton radiation therapy for tumors in the brain and spine. The new way, called intensity modulated proton radiation therapy (IMPT), may be more accurate and have fewer side effects than the standard proton radiation therapy.
Popular Filters
Trials for Bone Cancer Patients
CAR T-cell Therapy
TIL Therapy for Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
Seclidemstat Access for Sarcoma
Recruiting3 awardsPhase 1 & 2
Santa Monica, California
This trial allows patients who have previously benefited from seclidemstat to continue their treatment. Seclidemstat is a drug that aims to stop cancer cells from growing by blocking essential proteins. The trial targets patients who are still seeing positive results.
Trials for Cancer Patients
Glutaminase Inhibitor
IACS-6274 +/− Bevacizumab/Paclitaxel for Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new drug to see if it's safe and effective in treating patients with advanced solid tumors. The new drug, IACS-6274, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IACS-6274 with or without pembrolizumab may help to control the disease.
Virus Therapy
AdAPT-001 for Cancer
Recruiting1 awardPhase 2
San Marcos, California
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
CAR T-cell Therapy
TIL Therapy for Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Trials With No Placebo
Glutaminase Inhibitor
IACS-6274 +/− Bevacizumab/Paclitaxel for Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new drug to see if it's safe and effective in treating patients with advanced solid tumors. The new drug, IACS-6274, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IACS-6274 with or without pembrolizumab may help to control the disease.
Virus Therapy
AdAPT-001 for Cancer
Recruiting1 awardPhase 2
San Marcos, California
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.